Hemophagocytic Lymphohistiocytosis Completed Phase 2 Trials for Hydrocortisone (DB00741)

Back to Hemophagocytic Lymphohistiocytosis

Also known as: Hemophagocytic Lymphohistiocytosis (HLH) / Haemophagocytic Lymphohistiocytosis / Hemophagocytic Lymphohistiocytoses / Hemophagocytic Lymphohisticytosis / Hemophagocytic lymphohistiocytosis (disorder) / Lymphohistiocytosis, Hemophagocytic / Primary hemophagocytic lymphohistiocytosis / Primary haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis (disorder) / Familial Hemophagocytic Lymphocytosis / Familial haemophagocytic lymphohistiocytosis / Familial hemophagocytic lymphohistiocytosis

Indication	Status	Phase
DBCOND0029166 (Hemophagocytic Lymphohistiocytosis)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01104025	Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis	Treatment	Antithymocyte immunoglobulin (rabbit) (DB00098) Dexamethasone (DB01234) Etoposide (DB00773) Hydrocortisone (DB00741) Methotrexate (DB00563)